Alveus Therapeutics has debuted with $160m in Series A financing, as the biotech looks to join the crowded obesity sector ...

With smart DMPK strategies, cross-domain collaboration, and strong CDMO support, companies are pushing past the challenges of ...

Thymalin is a polypeptide complex derived from thymic preparations (often of bovine or calf origin), known to harbor among ...

What started out as a medication for diabetes and weight loss is offering something quite unexpected for many women. Experts ...

Scientists have discovered a new CRISPR mechanism with precise activity, expanding the potential applications of the existing ...

Looking to overcome some of the limitations of existing obesity drugs, Alveus Therapeutics has debuted with nearly $160 ...

ALV-100 is a bifunctional glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist / glucagon-like peptide-1 receptor (GLP-1R) agonist fusion protein designed to deliver potent, durable ...

Viking Therapeutics, Inc. (Viking) , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the publication of ...

Peptides have emerged as critical tools in the investigation of physiological homeostasis, specifically in how biological systems manage energy substrates and recover from physical trauma. By ...

Researchers from Würzburg, Braunschweig, and the US identifiy Cas12a3 nuclease showing precise activity. Their study is ...

Alveus Therapeutics is a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, designed for sustained efficacy, improved tolerability, and ...

IND filing of ALV-200 and advancement of additional programs across the R&D pipeline ALV-100, a bifunctional GIPR antagonist / GLP-1R agonist, designed ...